Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Deficits in Prenatal Serine Biosynthesis Underlie the Mitochondrial Dysfunction Associated with the Autism-Linked FMR1 Gene.

Tytuł:
Deficits in Prenatal Serine Biosynthesis Underlie the Mitochondrial Dysfunction Associated with the Autism-Linked FMR1 Gene.
Autorzy:
Nolin SL; Department of Human Genetics, New York State Institute for Basic Research in Developmental Disabilities, Staten Island, NY 10314, USA.
Napoli E; Department of Molecular Biosciences, School of Veterinary Medicine, University of California, Davis, CA 95616, USA.
Flores A; Department of Molecular Biosciences, School of Veterinary Medicine, University of California, Davis, CA 95616, USA.; Medical Sciences Campus, Department of Biochemistry, University of Puerto Rico, PR00936 San Juan, Puerto Rico.
Hagerman RJ; Department of Pediatrics, University of California Davis Medical Center, Sacramento, CA 95817, USA.; The MIND Institute, University of California Davis Medical Center, Sacramento, CA 95817, USA.
Giulivi C; Department of Molecular Biosciences, School of Veterinary Medicine, University of California, Davis, CA 95616, USA.; The MIND Institute, University of California Davis Medical Center, Sacramento, CA 95817, USA.
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2021 May 30; Vol. 22 (11). Date of Electronic Publication: 2021 May 30.
Typ publikacji:
Journal Article
Język:
English
Imprint Name(s):
Original Publication: Basel, Switzerland : MDPI, [2000-
MeSH Terms:
Mutation*
Autistic Disorder/*genetics
Fragile X Mental Retardation Protein/*genetics
Fragile X Syndrome/*genetics
Mitochondria/*genetics
Serine/*deficiency
5' Untranslated Regions ; Adult ; Amniocentesis ; Amniotic Fluid/chemistry ; Autistic Disorder/diagnosis ; Autistic Disorder/metabolism ; Autistic Disorder/pathology ; Citric Acid Cycle/genetics ; Female ; Fetus ; Fibroblasts/metabolism ; Fibroblasts/pathology ; Fragile X Mental Retardation Protein/metabolism ; Fragile X Syndrome/diagnosis ; Fragile X Syndrome/metabolism ; Fragile X Syndrome/pathology ; Gene Expression ; Genetic Complementation Test ; Heterozygote ; Humans ; Male ; Metabolomics/methods ; Mitochondria/metabolism ; Mitochondria/pathology ; Pregnancy ; Primary Cell Culture ; Proteomics/methods ; Serine/biosynthesis ; Trinucleotide Repeats
References:
PLoS One. 2011;6(6):e21635. (PMID: 21738743)
Nat Commun. 2018 Dec 21;9(1):5442. (PMID: 30575741)
Mov Disord. 2007 Oct 31;22(14):2018-30, quiz 2140. (PMID: 17618523)
Genet Med. 2018 Dec;20(12):1627-1634. (PMID: 29595813)
Hum Mol Genet. 2014 Mar 15;23(6):1399-412. (PMID: 24154540)
Nucleic Acids Res. 2019 Jan 8;47(D1):D607-D613. (PMID: 30476243)
Am J Obstet Gynecol. 2010 Jul;203(1):76.e1-76.e10. (PMID: 20435286)
Mol Cell. 2017 Mar 2;65(5):917-931.e6. (PMID: 28238651)
Am J Hum Genet. 2003 Feb;72(2):454-64. (PMID: 12529854)
Cell Metab. 2015 Aug 4;22(2):304-11. (PMID: 26212717)
Mol Cell Proteomics. 2007 Aug;6(8):1406-15. (PMID: 17495049)
Neurosci Res. 1998 Feb;30(2):195-9. (PMID: 9579653)
Mitochondrion. 2009 Jun;9(3):204-10. (PMID: 19460290)
J Cell Biol. 2016 Aug 1;214(3):249-57. (PMID: 27458133)
Neurology. 2002 Nov 12;59(9):1406-11. (PMID: 12427892)
N Engl J Med. 1976 Jul 1;295(1):51. (PMID: 58380)
Nucleic Acids Res. 2018 Jan 4;46(D1):D1271-D1281. (PMID: 29106664)
J Med Genet. 1975 Jun;12(2):138-51. (PMID: 49425)
Proc Natl Acad Sci U S A. 1999 Oct 12;96(21):12079-84. (PMID: 10518579)
J Neuropathol Exp Neurol. 2020 Apr 1;79(4):393-406. (PMID: 32077471)
Mol Cell. 2016 Mar 3;61(5):705-719. (PMID: 26942675)
PLoS One. 2011;6(10):e26116. (PMID: 22028811)
FASEB J. 2016 Oct;30(10):3334-3351. (PMID: 27335370)
Mol Neurobiol. 2017 Nov;54(9):6896-6902. (PMID: 27771901)
Mol Cell Biol. 2002 Nov;22(21):7614-21. (PMID: 12370308)
Biochem J. 2010 Aug 1;429(3):545-52. (PMID: 20513237)
EMBO J. 2002 Apr 2;21(7):1695-703. (PMID: 11927553)
Pediatrics. 2017 Jun;139(Suppl 3):S172-S182. (PMID: 28814538)
Front Genet. 2018 Aug 27;9:338. (PMID: 30210529)
Mol Cell Biol. 2003 Feb;23(3):916-22. (PMID: 12529397)
Biochem J. 1987 Jul 15;245(2):609-12. (PMID: 3117048)
Nat Protoc. 2008;3(6):965-76. (PMID: 18536644)
Cell Metab. 2020 Mar 3;31(3):503-517.e8. (PMID: 32130882)
Hum Mol Genet. 2016 Nov 1;25(21):4674-4685. (PMID: 28173120)
BMB Rep. 2018 Nov;51(11):549-556. (PMID: 30269744)
Biochem J. 2003 Mar 15;370(Pt 3):751-62. (PMID: 12467494)
Lancet. 2004 Dec 18-31;364(9452):2221-2. (PMID: 15610810)
Mol Psychiatry. 2012 Jul;17(8):827-40. (PMID: 21727898)
ACS Chem Biol. 2015 Feb 20;10(2):510-6. (PMID: 25406093)
Nat Commun. 2016 Apr 29;7:11457. (PMID: 27126896)
Guys Hosp Rep. 1974;123(2):121-9. (PMID: 4143202)
Cerebellum. 2016 Oct;15(5):552-64. (PMID: 27089882)
Neurology. 2001 Jul 10;57(1):127-30. (PMID: 11445641)
Cell Metab. 2011 Jul 6;14(1):80-90. (PMID: 21723506)
Reprod Biomed Online. 2003 Sep;7(2):250-3. (PMID: 14567901)
Hum Genet. 2020 Feb;139(2):227-245. (PMID: 31919630)
Hum Mol Genet. 2011 Aug 1;20(15):3079-92. (PMID: 21558427)
Methods Enzymol. 2002;349:9-23. (PMID: 11912933)
Cell Cycle. 2014;13(16):2600-8. (PMID: 25486200)
Oncotarget. 2017 Dec 7;9(1):680-690. (PMID: 29416645)
Mol Med. 2016 Oct;22:548-559. (PMID: 27385396)
J Neurodev Disord. 2016 Nov 3;8:40. (PMID: 27822316)
Semin Neurol. 2014 Jul;34(3):258-65. (PMID: 25192504)
Nucleic Acids Res. 2016 Jan 4;44(D1):D471-80. (PMID: 26527732)
PLoS One. 2016 Apr 12;11(4):e0152740. (PMID: 27070784)
Front Neurosci. 2016 Apr 19;10:159. (PMID: 27147951)
Biochem J. 1998 Jun 15;332 ( Pt 3):673-9. (PMID: 9620869)
Biochem J. 2016 Nov 1;473(21):3871-3888. (PMID: 27555610)
Biochem J. 2004 Jun 15;380(Pt 3):919-28. (PMID: 15018610)
Ann Glob Health. 2016 Jan-Feb;82(1):41-99. (PMID: 27325067)
Am J Med Genet A. 2019 Jul;179(7):1148-1156. (PMID: 31050164)
J Neurochem. 1995 Jul;65(1):454-8. (PMID: 7790891)
Brain. 2006 Jan;129(Pt 1):256-71. (PMID: 16246864)
Placenta. 2007 Aug-Sep;28(8-9):824-32. (PMID: 17303237)
Cell Tissue Res. 2003 Oct;314(1):119-29. (PMID: 12955493)
Proc Natl Acad Sci U S A. 1997 Oct 14;94(21):11168-72. (PMID: 9326580)
PLoS Comput Biol. 2015 Feb 23;11(2):e1004085. (PMID: 25706687)
J Clin Epidemiol. 2003 Sep;56(9):826-32. (PMID: 14505766)
Mol Genet Metab. 2008 May;94(1):16-37. (PMID: 18243024)
Nat Rev Drug Discov. 2013 Jun;12(6):465-83. (PMID: 23666487)
MAGMA. 2009 Dec;22(6):343-52. (PMID: 19779747)
Mol Cell Biol. 2004 Dec;24(24):10933-40. (PMID: 15572694)
Hum Mol Genet. 2010 Jan 1;19(1):170-80. (PMID: 19837698)
Eur J Hum Genet. 1993;1(1):72-9. (PMID: 8069653)
Curr Protoc Bioinformatics. 2019 Dec;68(1):e86. (PMID: 31756036)
Front Psychiatry. 2012 Apr 25;3:39. (PMID: 22539927)
Grant Information:
HD036071 National Institute of Child Health and Human Development
Contributed Indexing:
Keywords: CGG repeats; FMR1; amniotic fluid; metabolomics; premutation; proteomics
Substance Nomenclature:
0 (5' Untranslated Regions)
0 (FMR1 protein, human)
139135-51-6 (Fragile X Mental Retardation Protein)
452VLY9402 (Serine)
Entry Date(s):
Date Created: 20210602 Date Completed: 20210623 Latest Revision: 20210623
Update Code:
20240104
PubMed Central ID:
PMC8198117
DOI:
10.3390/ijms22115886
PMID:
34070950
Czasopismo naukowe
Fifty-five to two hundred CGG repeats (called a premutation, or PM) in the 5'-UTR of the FMR1 gene are generally unstable, often expanding to a full mutation (>200) in one generation through maternal inheritance, leading to fragile X syndrome, a condition associated with autism and other intellectual disabilities. To uncover the early mechanisms of pathogenesis, we performed metabolomics and proteomics on amniotic fluids from PM carriers, pregnant with male fetuses, who had undergone amniocentesis for fragile X prenatal diagnosis. The prenatal metabolic footprint identified mitochondrial deficits, which were further validated by using internal and external cohorts. Deficits in the anaplerosis of the Krebs cycle were noted at the level of serine biosynthesis, which was confirmed by rescuing the mitochondrial dysfunction in the carriers' umbilical cord fibroblasts using alpha-ketoglutarate precursors. Maternal administration of serine and its precursors has the potential to decrease the risk of developing energy shortages associated with mitochondrial dysfunction and linked comorbidities.
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies